1. Patient- and clinician-reported outcomes for the additively manufactured sub-periosteal jaw implant (AMSJI) in the maxilla: a prospective multicentre one-year follow-up study
- Author
-
Marco Rinaldi, Maurice Y. Mommaerts, Geert Klomp, Natalie A J Loomans, Ignace Naert, Ludovic Beckers, B. De Neef, H. Schouten, M.M. Freilich, Constantinus Politis, L. Van Doorne, C. Van den Borre, Erik Nout, Faculty of Medicine and Pharmacy, Surgical clinical sciences, and Oro-Maxillo-Facial Surgery
- Subjects
medicine.medical_treatment ,Alveolar Bone Loss ,Dentistry ,Prosthesis ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Atrophy ,Quality of life ,Rating scale ,medicine ,Maxilla ,Humans ,Jaw, Edentulous ,Patient Reported Outcome Measures ,Prospective Studies ,Dental Implants ,Rehabilitation ,business.industry ,Dental Implantation, Endosseous ,030206 dentistry ,medicine.disease ,Treatment Outcome ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Quality of Life ,Surgery ,Dental Prosthesis, Implant-Supported ,Oral Surgery ,Jaw implant ,business ,Follow-Up Studies - Abstract
The clinical outcomes of maxillary rehabilitation with the additively manufactured sub-periosteal jaw implant (AMSJI; CADskills BV) were evaluated in edentulous patients with a Cawood-Howell atrophy classification ≥5 in all regions of the maxilla. Fifteen consecutive patients were included in the study and followed up for 1 year. They were interviewed using a survey protocol and were examined clinically and radiographically preoperatively (T0) and at 1 (T1), 6 (T2), and 12 (T3) months after permanent upper prosthesis placement. The patients reported an increased oral health-related quality of life. The overall mean Oral Health Impact Profile-14 score at T0 was 17.20 (standard deviation (SD) 6.42). When results at T0 were compared to those at T1 (mean 8.93, SD 5.30), a statistically significant difference was seen (P = 0.001). At T3, the mean value was 5.80 (SD 4.18). Compared to T0, there was also a statistically significant difference at T3 (P = 0.001). General satisfaction based on the numerical rating scale was a mean 49.93 at T1, which was less than patient expectation prior to treatment at T0 (52.13). A higher overall value was seen at T3 (53.20) when compared to T0. Within the constraints of the short follow-up, the AMSJI appears to be a promising tool for patients with extreme jaw atrophy. The high patient expectations were met without complications.
- Published
- 2022